With an FDA de­ci­sion loom­ing, Flex­ion touts new da­ta spot­light­ing a safe­ty edge for os­teoarthri­tis drug

Now that Flex­ion $FLXN is less than four months away from an FDA de­ci­sion on its new os­teoarthri­tis drug Zil­ret­ta (FX006), the biotech has float­ed some new da­ta from a tiny mid-stage study that it’s hop­ing will find its way in­to the la­bel.

The Burling­ton, MA-based group turned up at the ADA meet­ing in San Diego over the week­end to say that it now has da­ta to prove that its drug is not as­so­ci­at­ed with the same spikes in blood glu­cose that di­a­bet­ics com­mon­ly ex­pe­ri­ence when they get a steroid shot in an aching joint. And they’re look­ing to use it to gain a leg up in a siz­able mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER